Targeted PET imaging could revolutionize cancer treatment selection

NCT ID NCT07554742

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new PET imaging tracer, [68Ga]Ga-NODAGA-SNA014, to detect a protein called Claudin18.2 in pancreatic and stomach cancers. The goal is to see if the scan can accurately identify patients whose tumors have this protein, which could help doctors choose the right targeted therapy. The trial will involve 64 participants with confirmed cancer and will compare scan results with tissue samples.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
[68Ga]Ga-NODAGA-SNA014 (a radioactive tracer for PET imaging)
What this could lead to
If successful, this imaging method could help doctors identify which patients are most likely to benefit from Claudin18.2-targeted therapies, enabling more personalized cancer treatment.
What could go wrong
This is an early-stage imaging study with only 64 participants, so results may not apply to all patients. The tracer's accuracy and safety are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.